How can standard risk multiple myeloma (MM) patients be cured?
Insights from the RAY trial: treating relapsed mantle cell lymphoma patients
iFCG: a promising new regimen for treating IGHV-mutated CLL
How durable are the responses of CLL patients to therapy?
Inside the German CLL Study Group's annual workshop